Are Th17 cells and their cytokines a therapeutic target in Guillain–Barré syndrome?

Bibliography

• van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain-Barré syndrome. Expert Rev Clin Immunol 2013;9:627-39
   PubMed Web of Science ®Google Scholar
• Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-20
   PubMed Web of Science ®Google Scholar
• Govoni V, Granieri E, Manconi M, et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci 2003;216:99-103
   PubMed Web of Science ®Google Scholar
• Gensicke H, Datta AN, Dill P, et al. Increased incidence of Guillain-Barré syndrome after surgery. Eur J Neurol 2012;19:1239-44
   PubMed Web of Science ®Google Scholar
• Wakerley BR, Yuki N. Surgery itself does not trigger Guillain-Barré syndrome. Eur J Neurol 2013;20:e40
   PubMed Web of Science ®Google Scholar
• Wu X, Wu W, Wang Z, et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China. PLoS ONE 2014;9:e104074
   PubMed Web of Science ®Google Scholar
• McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32:150-63
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33
   PubMed Web of Science ®Google Scholar
• Zhang HL, Zheng XY, Zhu J. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis. Cytokine Growth Factor Rev 2013;24:443-53
   PubMed Web of Science ®Google Scholar
• Sheikh KA, Zhang G, Gong Y, et al. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 2004;56:228-39
   PubMed Web of Science ®Google Scholar
• Tatsumoto M, Koga M, Gilbert M, et al. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a. J Neuroimmunol 2006;177:201-8
   PubMed Web of Science ®Google Scholar
• Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9
   PubMed Web of Science ®Google Scholar
• Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83:23-8
   PubMed Web of Science ®Google Scholar
• Hartung HP, Lehmann HC, Kieseier BC, et al. Novel treatment for immune neuropathies on the horizon. J Peripher Nerv Syst 2011;16:75-83
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Hughes RA, Kieseier BC, et al. Recent developments and future directions in Guillain-Barr´ e syndrome. J Peripher Nerv Syst 2012;17:57-70
   PubMedGoogle Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40
   PubMed Web of Science ®Google Scholar
• Hemdan NY, Abu El-Saad AM, Sack U. The role of T helper (TH)17 cells as a double-edged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation. Clin Dev Immunol 2013;2013:374-769
   Google Scholar
• Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517
   PubMed Web of Science ®Google Scholar
• van den Berg WB, McInnes IB. Th17 cells and IL-17 A—Focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43:158-70
   PubMed Web of Science ®Google Scholar
• Nyati KK, Prasad KN, Rizwan A, et al. TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 2011;68:445-52
   PubMed Web of Science ®Google Scholar
• Zhu J, Bai XF, Mix E, et al. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 beta, IL-6, IL-10, IL-12, TNF-alpha, TNF-beta, and cytolysin. Clin Immunol Immunopathol 1997;84:85-94
   PubMedGoogle Scholar
• Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Gulllain-Barré syndrome. J Neuroimmunol 1998;84:40-52
   PubMed Web of Science ®Google Scholar
• Bao L, Lindgren JU, van der Meide P, et al. The critical role of IL12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental auotimmmune neuritis. Brain Pathol 2002;12:420-9
   PubMed Web of Science ®Google Scholar
• Hartung HP, Schäfer B, van der Meide PH, et al. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol 1990;27:247-57
   PubMed Web of Science ®Google Scholar
• Hartung HP, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1990;27:S57-63
   PubMedGoogle Scholar
• Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res Immunol 1992;143:589-99
   PubMedGoogle Scholar
• Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol 1998;87:27-32
   PubMed Web of Science ®Google Scholar
• Deretzi G, Pelidou SH, Zou LP, et al. Local effects of recombinant rat interleukin-6 on the peripheral nervous system. Immunology 1999;97:582-7
   PubMed Web of Science ®Google Scholar
• Deretzi G, Zou LP, Pelidou HS, et al. Nasal administration of recombinant rat IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination. J Autoimmunity 1999;12:81-9
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Wolfe GI. Cytokines in Guillain-Barré syndrome: a lesson in time. Arch Neurol 2011;68:427-8
   PubMed Web of Science ®Google Scholar
• Zhang HL, Azimullah S, Zheng XY, et al. IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. J Neuroimmunol 2012;246:18-26
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 2006;441:231-4
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
   PubMed Web of Science ®Google Scholar
• Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-β are required for differentiation of human TH17 cells. Nature 2008;454:350-2
   PubMed Web of Science ®Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-βand induction of the nuclear receptor RORγt. Nat Immunol 2008;9:641-9
   PubMed Web of Science ®Google Scholar
• Maddur MS, Miossec P, Kaveri SV, et al. Th17 cells:biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012;181:8-18
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25− naïve T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007;448:484-7
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-14
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-33
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, et al. T helper17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29-39
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007;282:9358-63
   PubMed Web of Science ®Google Scholar
• Mathur AN, Chang HC, Zisoulis DG, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007;178:4901-7
   PubMed Web of Science ®Google Scholar
• Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: an in vivo requirement or STAT3 signaling in Th17 development and Th17-dependent autoimmunity. J Immunol 2007;179:4313-17
   PubMed Web of Science ®Google Scholar
• Brüstle A, Heink S, Huber M, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007;8:958-66
   PubMed Web of Science ®Google Scholar
• Zhang X, Tao Y, Troiani L, et al. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol 2011;187:3431-7
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008;453:106-9
   PubMed Web of Science ®Google Scholar
• Keerthivasan S, Suleiman R, Lawlor R, et al. Notch signaling regulates mouse and human Th17 differentiation. J Immunol 2011;187:692-701
   PubMed Web of Science ®Google Scholar
• Schraml BU, Hildner K, Ise W, et al. The AP-1 transcription factor Batf controls T H 17 differentiation. Nature 2009;460:405-9
   PubMed Web of Science ®Google Scholar
• Tuomela S, Salo V, Tripathi SK, et al. Identification of early gene expression changes during human Th17 cell differentiation. Blood 2012;119:e151-60
   Google Scholar
• Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008;9:1297-306
   PubMed Web of Science ®Google Scholar
• Zhou L, Lopes JE, Chong MM, et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 2008;453:236-40
   PubMed Web of Science ®Google Scholar
• Elias KM, Laurence A, Davidson TS, et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008;111:1013-20
   PubMed Web of Science ®Google Scholar
• Xiao S, Jin H, Korn T, et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-β-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008;181:2277-84
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cellmediated autoimmunity to environmental toxins. Nature 2008;453:106-9
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Murugaiyan G, Farez MF, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010;107:20768-73
   PubMed Web of Science ®Google Scholar
• Gandhi R, Kumar D, Burns EJ, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010;11:846-53
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Chen X, Shim JH, et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat Immunol 2011;12:96-104
   PubMed Web of Science ®Google Scholar
• van Hamburg JP, de Bruijn MJ, Ribeiro de Almeida C, et al. Enforced expression of GATA3 allows differentiation of IL-17-producing cells, but constrains Th17-mediated pathology. Eur J Immunol 2008;38:2573-86
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007;26:371-81
   PubMed Web of Science ®Google Scholar
• Moisan J, Grenningloh R, Bettelli E, et al. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007;204:2825-35
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Wang L, et al. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011;12:551-9
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42
   PubMed Web of Science ®Google Scholar
• Fitzgerald DC, Ciric B, Touil T, et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;179:3268-75
   PubMed Web of Science ®Google Scholar
• Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-36
   PubMed Web of Science ®Google Scholar
• Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007;8:1363-71
   PubMed Web of Science ®Google Scholar
• Fitzgerald DC, Zhang GX, El-Behi M, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-9
   PubMed Web of Science ®Google Scholar
• Shiomi A, Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm 2015;2015:568543
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Sheikh F, Dickensheets H, et al. Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev 2010;21:393-401
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011;23:1069-75
   PubMed Web of Science ®Google Scholar
• Wang X, Chi Ma, Jiang Wu, et al. The roles of T helper 17 cells and IL-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barré syndrome as well as their animal models. J Neurosc Res 2013;91:871-81
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity 2011;34:149-62
   PubMed Web of Science ®Google Scholar
• Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009;30:108-19
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205:1063-75
   PubMed Web of Science ®Google Scholar
• Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 2010;21:435-41
   PubMed Web of Science ®Google Scholar
• Li S, Yu M, Li H, et al. IL-17 and IL-22 in Cerebrospinal Fluid and Plasma Are Elevated in Guillain-Barre Syndrome. Mediators Inflamm 2012;2012:260473
   PubMed Web of Science ®Google Scholar
• Liang SL, Wang WZ, Huang S, et al. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome. Immunopharmacol Immunotoxicol 2012;34:1039-46
   PubMed Web of Science ®Google Scholar
• Li S, Jin T, Zhang HL, et al. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments. Mediators Inflamm 2014;2014:740947
   PubMed Web of Science ®Google Scholar
• Han RK, Cheng YF, Zhou SS, et al. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome. J Clin Immunol 2014;34:94-103
   PubMed Web of Science ®Google Scholar
• Pelidou SH, Zou LP, Deretzi G, et al. Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Exp Neurol 2000;163:165-72
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng XY, Ma C, et al. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis. Scand J Immunol 2014;80:180-90
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Zhang Z, Schluesener HJ. FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol 2009;35:487-95
   PubMed Web of Science ®Google Scholar
• Li XL, Dou YC, Liu Y, et al. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol 2011;271:455-61
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Zhang Z, Zug C, et al. AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 2009;216:59-65
   PubMed Web of Science ®Google Scholar
• Yi C, Zhang Z, Wang W, et al. Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res 2011;36:1984-90
   PubMed Web of Science ®Google Scholar
• Han F, Luo B, Shi R, et al. Curcumin ameliorates rat experimental autoimmune neuritis. J Neurosci Res 2014;92:743-50
   PubMed Web of Science ®Google Scholar
• Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome. J Clin Neurosci 2008;15:1031-5
   PubMed Web of Science ®Google Scholar
• Pritchard J, Makowska A, Gregson NA, et al. Reduced circulating CD4+CD25+ cell populations in Guillain-Barré syndrome. J Neuroimmunol 2007;183:232-8
   PubMed Web of Science ®Google Scholar
• Chi LJ, Wang HB, Zhang Y, et al. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol 2007;192:206-14
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang ZY, Fauser U, et al. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008;65:4055-65
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang ZY, Schluesener HJ. Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 2009;183:3081-91
   PubMed Web of Science ®Google Scholar
• Maddur MS, Rabin M, Hegde P, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients. Immunol Res 2014;60:320-9
   PubMed Web of Science ®Google Scholar
• Hu W, Dehmel T, Pirhonen J, et al. Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Arch Neurol 2006;63:858-64
   PubMed Web of Science ®Google Scholar
• van den Berg WB, McInnes IB. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43:158-70
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012;122:487-511
   PubMed Web of Science ®Google Scholar
• Yang J, Sundrud MS, Skepner J, et al. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci 2014;35:493-500
   PubMed Web of Science ®Google Scholar
• Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012;11:159-68
   PubMedGoogle Scholar
• Huh JR, Littman DR. Small molecule inhibitors of RORγt:targeting Th17 cells and other applications. Eur J Immunol 2012;42:2232-7
   PubMed Web of Science ®Google Scholar
• Skepner J, Trocha M, Ramesh R, et al. In vivo regulation of gene expression and Th17 differentiation by RORγt inverse agonists. Immunology 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168:412-21
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168:402-11
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66:1693-704
   PubMed Web of Science ®Google Scholar
• Luchtman DW, Ellwardt E, Larochelle C, et al. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Rev 2014;25:403-13
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72:863-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014;41:414-21
   PubMed Web of Science ®Google Scholar
• Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexateresistant rheumatoid arthritis. Arthritis Res Ther 2013;15:R164
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700
   PubMed Web of Science ®Google Scholar
• McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 2001;194:873-82
   PubMed Web of Science ®Google Scholar
• Ponomarev ED, Shriver LP, Maresz K, et al. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007;178:39-48
   PubMed Web of Science ®Google Scholar
• Cornish AL, Campbell IK, McKenzie BS, et al. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009;5:544-9
   Web of Science ®Google Scholar
• Koenders MI, van den Berg WB. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci 2015;36:189-95
   PubMed Web of Science ®Google Scholar
• Be’eri H, Reichert F, Saada A, et al. The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Eur J Neurosci 1998;10:2707-13
   PubMed Web of Science ®Google Scholar
• Saada A, Reichert F, Rotshenker S. Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up-regulation of cell surface expression of MAC-2 by macrophages and Schwann cells. J Cell Biol 1996;133:159-67
   PubMed Web of Science ®Google Scholar
• Behrens F, Tak PP, Ostergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tanaka Y, Close D, et al. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod Rheumatol 2015;25:21-30
   PubMed Web of Science ®Google Scholar
• Croxford AL, Mair F, Becher B. IL-23: One cytokine in control of autoimmunity. Eur J Immunol 2012;42:2263-73
   PubMed Web of Science ®Google Scholar
• Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-24
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Taylor PC, Buckley CD. The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases. Curr Opin Rheumatol 2015;27:71-5
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519-28
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009;9:319-21
   PubMed Web of Science ®Google Scholar
• Papp KA, Sundaram M, Bao Y, et al. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2014;28:790-8
   PubMed Web of Science ®Google Scholar
• Langley RG, Papp K, Gottlieb AB, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2013;27:1252-61
   PubMed Web of Science ®Google Scholar
• Traczewski P, Rudnicka L. Briakinumab for the treatment of plaque psoriasis. BioDrugs 2012;26:9-20
   PubMed Web of Science ®Google Scholar
• Huh JR, Leung MW, Huang P, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 2011;472:486-90
   PubMed Web of Science ®Google Scholar
• Fujita-Sato S, Ito S, Isobe T, et al. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J Biol Chem 2011;286:31409-17
   PubMed Web of Science ®Google Scholar
• Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011;472:491-4
   PubMed Web of Science ®Google Scholar
• Xu T, Wang X, Zhong B, et al. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem 2011;286:22707-10
   PubMed Web of Science ®Google Scholar
• Xiao S, Yosef N, Yang J, et al. Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014;40:477-89
   PubMed Web of Science ®Google Scholar
• Skepner J, Ramesh R, Trocha M, et al. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol 2014;192:2564-75
   PubMed Web of Science ®Google Scholar
• Skepner J, Trocha M, Ramesh R, et al. In vivo regulation of gene expression and Th17 differentiation by RORγt inverse agonists. Immunology 2015; Epub ahead of print
   PubMed Web of Science ®Google Scholar